News & Events:HOLX

Index Finds Women’s Health Needs Are Not Being Met Globally and Provides Data Roadmap for Improvement Analysis Identifies Five Health Dimensions that Correlate with Women’s Life Expectancy Hologic, Inc. (HOLX), a global leader in women's health, today shared the findings from its inaugural Hologic Global Women’s Health Index, the world’s most comprehensive, globally comparative survey about women’s he...

Hologic, Inc. (HOLX) announced today that the Company will present at these upcoming virtual investor conferences: Each presentation will be webcast live and may be accessed through a link on the investors section of Hologic’s website at http://investors.hologic.com. The webcasts will be available for 30 days following the events.

Coverage Further Validates Laparoscopic Radiofrequency Ablation for Women with Uterine Fibroids Hologic, Inc. (HOLX), a global leader in women’s health, announced today that Anthem Blue Cross Blue Shield, the second largest health plan in the United States, has updated its medical policy to cover Radiofrequency Ablation, which includes the Acessa® procedure, for women suffering from uterine fibroids.

NEW YORK, Aug. 9, 2021 While most of the economy has reopened, the number of new cases is once again on the rise. As a result, the highly transmissible delta variant now accounts for 83% of all positive samples. in New York City. As of last Friday, all five boroughs of the city have met the CDC guidelines to be considered "high transmission" areas where extra precautions should be taken.

Hologic Inc (HOLX): * HOLOGIC ANNOUNCES FINANCIAL RESULTS FOR THIRD QUARTER OF FISCAL 2021. * Q3 REVENUE $1.168 BILLION VERSUS REFINITIV IBES ESTIMATE OF $1.04 BILLION. * Q3 NON-GAAP EARNINGS PER SHARE $1.33. * Q3 GAAP EARNINGS PER SHARE $1.04. * Q3 EARNINGS PER SHARE ESTIMATE $1.12 -- REFINITIV IBES DATA. * SEES Q4 REVENUE $1,000 MILLION - $1,040 MILLION.

— Revenue of $1.168 Billion Increases 42.0%, 37.8% in Constant Currency —. — Organic Revenue Increases 38.4%, 34.2% in Constant Currency —. — Company Posts GAAP Diluted EPS of $1.04, Non-GAAP Diluted EPS of $1.33 —. Hologic, Inc. (HOLX) announced today the Company’s financial results for the fiscal third quarter ended June 26, 2021.

With STIs reaching a new high for the sixth consecutive year, a more inclusive screening approach is considered for chlamydia and gonorrhea in women under 25 First CDC guidelines to recommend testing specific populations for Mycoplasma genitalium, which was previously listed as an emerging issue MARLBOROUGH, Mass.

NEW YORK, July 20, 2021 Concerns over the pandemic are once again in the forefront as the Delta strain has become the driving force of new COVID surge. Even though vaccines are available and are being rolled out, testing remains a crucial factor.

Hologic Inc (HOLX): * HOLOGIC OBTAINS EUROPEAN CE MARK FOR USE OF SALIVA SAMPLES WITH COVID-19 TEST Source text for Eikon: Further company coverage:

Hologic, Inc. (HOLX) has obtained a CE Mark for the use of saliva samples with the Aptima® SARS-CoV-2 assay in Europe. “This new CE Mark demonstrates our commitment to providing European consumers and healthcare providers as many options as possible to manage the ongoing pandemic,” said Jan Verstreken, Hologic’s group president, International. Collection of saliva is easy, noninvasive and painless.

Hologic, Inc. (HOLX) announced today that the Company plans to release its financial results for the third quarter of fiscal 2021 on Wednesday, July 28, after the market closes. Interested participants may listen to the call by dialing 888-204-4368 or +1 323-994-2093 and referencing access code 5101679.